Recent Developments in Meibomian Gland Dysfunction and Treatment Market
Meibomian gland dysfunction (MGD) is a disorder in which the glands either do not secrete enough oil or secrete oil of low quality. The global meibomian gland dysfunction treatment market was estimated worth USD 158.6 billion in 2021 and the industry is estimated to grow at a significant pace at a CAGR of 9.2% over the projected period, as per a recent market analysis by Quince Market Insights. MGD is a very prevalent condition. Patients with MGD are frequently asymptomatic in the early stages, but if left untreated, it can cause or exacerbate dry eye symptoms and eyelid irritation. The oil gland becomes clogged when the secretions thicken. When glands become chronically clogged, they lose their ability to release oil, resulting in irreversible alterations in the tear film and dry eyes.
Impact of coronavirus (covid-19) pandemic on the Meibomian Gland Dysfunction and Treatment Market
COVID-19 has affected production and demand, disrupted distribution channels, and affected businesses. The disease has spread to over 100 nations around the world since the COVID-19 viral outbreak in December 2019, prompting the World Health Organization to declare it a public health emergency.
Furthermore, due to the COVID-19 pandemic, participants in the meibomian gland dysfunction and treatment industry are facing substantial difficulties. With travel restrictions, the supply of raw materials for making pharmaceutical formulations is a severe challenge. In addition, pharmaceutical wholesalers are dealing with erratic demand from retailers.
Recent Advances in the Meibomian Gland Dysfunction and Treatment Market
MGD is one of the most common conditions seen by ophthalmologists, and it can result in inflammation, hypersecretion, and aberrant excreta from the meibomian glands. Because of the rising awareness of MGD's importance, MGD therapy has received a lot of attention. Although there are a lot of traditional therapeutic options for obstructed meibum, such as warm compresses and lid cleanliness, as well as antibiotics and anti-inflammatory medicines to improve the quality of meibum, treating MGD remains difficult. These new MGD treatment alternatives could help to alleviate the disease's clinical symptoms and indicators.
Intraductal meibomian gland probing may provide long-term relief of MGD symptoms, possibly because of the orifice and central duct being re-established, as well as the elimination of aberrant meibum. Some lipid-containing emulsion eye drops could be used as an alternative treatment for MGD. LipiFlow is a unique procedure that simultaneously administers heat and pressure to the eyelid tissue to impact the meibomian glands. The LipiFlow thermal pulsation technology also appears to be safe and beneficial in the treatment of MGD.
NAC administrations, both systemic and topical, have been studied for their potential role in the treatment of MGD. Topical azithromycin therapy may result in clinical control or remission of MGD symptoms and signs, as well as improvements in the lipid characteristics of meibomian gland secretion; as a result, it may be a potentially useful and well tolerated MGD treatment. Omega-3 essential fatty acid nutritional supplementation could also be an alternative treatment for MGD. Finally, although the results of different trials are somewhat conflicting, cyclosporine A may be useful in the treatment of MGD.
Latest Developments in Meibomian Gland Dysfunction (MGD)
· In 2021 ThermaMEDx (U.S.) has unveiled a pre-moistened, self-heating, disposable, sterile cleaning eye-pad (EverTears). The product is used in treating the symptoms of dry eyes and meibomian gland dysfunction (MGD).
· In April 2021, Lumenis Ltd. (Israel) declared that the FDA has granted De Novo approval for Lumenis’ newest IPL device. The device will help improve dry eye due to meibomian gland dysfunction (MGD).
Some of the major biopharma companies eorking in this field are Pfizer, Inc., (U.S.), AbbVie Inc. (U.S.), Johnson and Johnson (U.S.), Bausch Health Companies Inc. (Canada), Alcon (Switzerland), RegeneRx (U.S.), Akorn, Inc. (U.S.), and Sentiss Pharma Pvt. Ltd (India).
Factors Causing the Meibomian Gland Dysfunction
The number of meibomian glands decreases as one gets older. Origin of a person plays a role as well; Asians are more likely to have MGD. People are more prone to get it with contact lenses.
If the Cholesterol and triglyceride levels are high, or if an individual has some other eye illnesses such as allergic conjunctivitis, eyelid or cornea that is inflamed or damaged or is infected with bacteria etc., then the chances of getting MGD are high.
Some Complications Related to MGD
The most prevalent cause of dry eye condition is MGD (also called dry eye disease). MGD can cause blepharitis, or inflammation of the eyelids, especially along the rims. These three circumstances have a lot of overlap, and it's conceivable to have all three at the same time. In fact, researchers aren't fully clear, which occurs first or how they're linked. It's possible that MGD causes dry eye by promoting inflammation, or that dry eye inflammation affects the meibomian glands. Untreated MGD raises postoperative risk of infection and inflammation for eye surgery. If MGD is not treated, it might lead to corneal degeneration.
For more info on the topic, check this link - https://www.quincemarketinsights.com/industry-analysis/meibomian-gland-dysfunction-treatment-market
Check our website
You can also contact us at - email@example.com